ECSP066927A - Sintesis regioespecífica de los derivados de 42 - ester de rapamicina - Google Patents

Sintesis regioespecífica de los derivados de 42 - ester de rapamicina

Info

Publication number
ECSP066927A
ECSP066927A EC2006006927A ECSP066927A ECSP066927A EC SP066927 A ECSP066927 A EC SP066927A EC 2006006927 A EC2006006927 A EC 2006006927A EC SP066927 A ECSP066927 A EC SP066927A EC SP066927 A ECSP066927 A EC SP066927A
Authority
EC
Ecuador
Prior art keywords
derivatives
regio
specific synthesis
rapamycin ester
rapamycin
Prior art date
Application number
EC2006006927A
Other languages
English (en)
Inventor
Jianxin Gu
Ping Cai
Mark E Ruppen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965235&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066927(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066927A publication Critical patent/ECSP066927A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención provee una síntesis catalizada por lipasas de derivados de 42-ésteres de rapamicinas. Las características remarcables de este proceso simple son la regioespecificidad y el excelente rendimiento bajo condiciones suaves.Otro aspecto y ventajas de la invención serán fácilmente aparentes a uno de habilidad en la técnica.
EC2006006927A 2004-04-14 2006-10-16 Sintesis regioespecífica de los derivados de 42 - ester de rapamicina ECSP066927A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56192604P 2004-04-14 2004-04-14

Publications (1)

Publication Number Publication Date
ECSP066927A true ECSP066927A (es) 2006-12-20

Family

ID=34965235

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006927A ECSP066927A (es) 2004-04-14 2006-10-16 Sintesis regioespecífica de los derivados de 42 - ester de rapamicina

Country Status (23)

Country Link
US (1) US7268144B2 (es)
EP (1) EP1737869A1 (es)
JP (1) JP4224115B2 (es)
KR (1) KR20070015544A (es)
CN (1) CN1942476A (es)
AR (1) AR049019A1 (es)
AU (1) AU2005238431A1 (es)
BR (1) BRPI0509852A (es)
CA (1) CA2562952A1 (es)
CL (1) CL2008000507A1 (es)
CR (1) CR8646A (es)
EC (1) ECSP066927A (es)
GT (1) GT200500085A (es)
IL (1) IL178315A0 (es)
MX (1) MXPA06011881A (es)
NO (1) NO20065090L (es)
PA (1) PA8629901A1 (es)
PE (1) PE20060253A1 (es)
RU (1) RU2387657C2 (es)
SG (1) SG152234A1 (es)
TW (1) TW200536542A (es)
UA (1) UA87492C2 (es)
WO (1) WO2005105811A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
AU2005238432A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
JP2007534337A (ja) * 2004-04-27 2007-11-29 ワイス ラパマイシン特異的メチラーゼを用いるラパマイシンの標識
WO2006038972A1 (en) * 2004-08-10 2006-04-13 Wyeth Cci-779 derivatives and methods of making same
MX2007009590A (es) 2005-02-09 2007-09-12 Wyeth Corp Polimorfo cci-779 y uso del mismo.
US7538119B2 (en) * 2005-11-04 2009-05-26 Wyeth 41-Methoxy isotope labeled rapamycin 42-ester
EP1957500A1 (en) * 2005-12-07 2008-08-20 Wyeth a Corporation of the State of Delaware Process for the preparation of purified crystalline cci-779
AR058283A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7622578B2 (en) * 2005-12-07 2009-11-24 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
BRPI0708562A2 (pt) * 2006-03-07 2011-06-07 Wyeth Corp processos para preparar conjugados de polietileno glicor de macrolìdeos imunossupressores, um macrolìdeo imunossupressor peguilado, uma rapamicina peguilada, um everolimus peguilado, um cci-779 peguilado e um tacrolimus peguilado, e, produto
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
IT1394309B1 (it) 2009-05-22 2012-06-06 Poli Ind Chimica Spa Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2828829A1 (en) * 2011-04-01 2012-10-04 Sandoz Ag Regioselective acylation of rapamycin at the c-42 position
US10751450B2 (en) 2012-06-08 2020-08-25 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
SG11201405777YA (en) * 2012-06-08 2014-10-30 Biotronik Ag Rapamycin 40-o-cyclic hydrocarbon esters, compositions and methods
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
ES2897473T3 (es) * 2013-03-15 2022-03-01 Biosensors Int Group Ltd Purificación de derivados de la rapamicina
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
BR112019016775A2 (pt) 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
AU2018370237A1 (en) * 2017-11-20 2020-06-04 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
EP3880266A1 (en) 2018-11-14 2021-09-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
US20220176084A1 (en) 2019-04-08 2022-06-09 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
US20240100025A1 (en) * 2020-12-14 2024-03-28 Biotronik Ag Materials and Methods for Treating Viral and Other Medical Conditions
EP4308105A1 (en) 2021-03-19 2024-01-24 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN118027062A (zh) * 2023-11-03 2024-05-14 沈阳药科大学 一种雷帕霉素前药及其纳米制剂的制备和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1319008T3 (da) 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
WO2005016935A2 (en) 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779
BRPI0414066A (pt) 2003-09-03 2006-10-24 Wyeth Corp 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha
EP1701698B1 (en) * 2004-01-08 2008-01-16 Wyeth a Corporation of the State of Delaware Directly compressible pharmaceutical composition for the oral admimistration of cci-779

Also Published As

Publication number Publication date
US7268144B2 (en) 2007-09-11
JP4224115B2 (ja) 2009-02-12
JP2007532134A (ja) 2007-11-15
PE20060253A1 (es) 2006-03-30
CA2562952A1 (en) 2005-11-10
AR049019A1 (es) 2006-06-21
CR8646A (es) 2007-08-28
BRPI0509852A (pt) 2007-10-23
UA87492C2 (en) 2009-07-27
WO2005105811A1 (en) 2005-11-10
SG152234A1 (en) 2009-05-29
NO20065090L (no) 2006-11-13
RU2387657C2 (ru) 2010-04-27
MXPA06011881A (es) 2006-12-14
CN1942476A (zh) 2007-04-04
GT200500085A (es) 2005-11-03
KR20070015544A (ko) 2007-02-05
CL2008000507A1 (es) 2008-07-04
TW200536542A (en) 2005-11-16
IL178315A0 (en) 2007-02-11
RU2006134014A (ru) 2008-05-20
EP1737869A1 (en) 2007-01-03
AU2005238431A1 (en) 2005-11-10
PA8629901A1 (es) 2006-06-02
US20050234234A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
ECSP066927A (es) Sintesis regioespecífica de los derivados de 42 - ester de rapamicina
SMP200700028B (it) Orologio da polso con funzione di auricolare telefonica
ITMI20050723A1 (it) Metodo di produzione del biodiesel
DK1948666T3 (da) HIV-intergrasehæmmere
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE450512T1 (de) Enantioselektive herstellung von chinolin- derivaten
EP1709832A4 (en) SPEAKER WITH EXTERNAL SCHALLANBAU
DE602005010641D1 (de) Plasmaanzeigetafel
ITMI20050255A1 (it) Trave di sostegno per sostenere una tavola da armatura
DE602005001217D1 (de) Dynamische Entzerrung
GB2450007A (en) Dynamic update adaptive idle timer
DE602005009469D1 (de) Plasma-Anzeigetafel
DE602005025848D1 (de) Plasmaanzeigetafel
DK1896485T3 (da) Azolopyridin-2-on-derivater som inhibitorer af lipaser og phospholipaser
DE602006007916D1 (de) Stimmprothese
FI20050811A (fi) Menetelmä biomassan luontaisen rakenteen hajottamiseksi
ITMI20051681A1 (it) Componente micromeccanico e corrispondente procedimento di produzione
DE112006001407A5 (de) Neues Fermentationsverfahren
FR2885254B1 (fr) Caisson de presentation
AU310936S (en) Portable speakers
DE602005023212D1 (de) Plasmaanzeigevorrichtung
DE602005018710D1 (de) Plasmaanzeigetafel
FR2875054B1 (fr) Support de substrats minces
DE602005005844D1 (de) Bewegliche stützkonstruktion
NO20050926D0 (no) Hoyttaler